Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

A panel of CDC advisers, who had originally been set to meet in February, will discuss the current measles outbreak as well ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs ...

Initially, Amvuttra’s annual list price will be nearly double the yearly cost of rival medicines from Pfizer and BridgeBio.

The PBM is pivoting to a cost-based reimbursement model, which it says will reduce variation in how pharmacies are paid.

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and ...

The PBM plans to stop requiring coverage authorization for about 80 drugs, including Vertex’s cystic fibrosis medicines and ...

The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...

Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...